Embolotherapy Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2025 - 2030)
Get a Comprehensive Overview of the Embolotherapy Market Report Prepared by P&S Intelligence, Segmented by Product (Embolic Agents, Support Devices), Procedure (Transcatheter Arterial Embolization, Transarterial Radioembolization/Selective Internal Radiation Therapy, Transarterial Chemoembolization), Indication (Cancer, Peripheral Vascular Diseases, Neurological Diseases, Urological and nephrological disorders, Gastrointestinal Disorders) End User (Hospitals and Clinics, Ambulatory Surgical Centers), and Geographic Regions. This Report Provides Insights From 2017 to 2024
Chapter 1. Research Background
1.1 Research Objectives
1.2 Market Definition
1.3 Analysis Period
1.4 Market Data Reporting Unit
1.4.1 Value
1.5 Market Size Breakdown by Segment
1.5.1 Market Segmentation by Product
1.5.2 Market Segmentation by Procedure
1.5.3 Market Segmentation by Indication
1.5.4 Market Segmentation by End User
1.5.5 Market Segmentation by Region
1.6 Key Stakeholders
Chapter 2. Research Methodology
2.1 Secondary Research
2.1.1 Paid
2.1.2 Unpaid
2.1.3 P&S Intelligence Database
2.2 Primary Research
2.2.1 Breakdown of Primary Research, by Region
2.2.2 Breakdown of Primary Research, by Industry Participant
2.2.3 Breakdown of Primary Research, by Company Type
2.3 Market Size Estimation
2.4 Data Triangulation
2.5 Currency Conversion Rates
Chapter 3. Executive Summary
Chapter 4. Introduction
4.1 Definition of Market Segments
4.1.1 By Product
4.1.1.1 Embolic agents
4.1.1.1.1 Microspheres
4.1.1.1.2 Bland PVA particles
4.1.1.1.3 Embolic coils
4.1.1.1.4 Liquid embolic agents
4.1.1.1.5 Embolic plug systems
4.1.1.1.6 Detachable balloons
4.1.1.2 Support devices
4.1.1.2.1 Microcatheters
4.1.1.2.2 Guidewires
4.1.2 By Procedure
4.1.2.1 TAE
4.1.2.2 TARE/SIRT
4.1.2.3 TACE
4.1.3 By Indication
4.1.3.1 Cancer
4.1.3.1.1 Kidney
4.1.3.1.2 Liver
4.1.3.1.3 Others
4.1.3.2 Peripheral vascular diseases
4.1.3.3 Neurological diseases
4.1.3.3.1 Cerebral aneurysms
4.1.3.3.2 Arteriovenous malformations and fistulas
4.1.3.4 Urological and nephrological disorders
4.1.3.5 Gastrointestinal disorders
4.1.4 By End User
4.1.4.1 Hospitals and clinics
4.1.4.2 ASCs
4.1.4.3 Others
4.2 Market Dynamics
4.2.1 Trends
4.2.1.1 Increasing number of product approvals and launches
4.2.1.2 Increasing number of acquisitions
4.2.1.3 Technological advancements in embolotherapy devices
4.2.2 Drivers
4.2.2.1 Increasing prevalence of chronic and lifestyle-associated diseases
4.2.2.2 Growing medical tourism sector
4.2.2.3 Rising healthcare expenditure and improving healthcare infrastructure
4.2.2.4 Surging patient preference for MISs
4.2.2.5 Impact analysis of drivers on market forecast
4.2.3 Restraints
4.2.3.1 Risks and challenges associated with embolization
4.2.3.2 Strong market positioning of alternative therapies
4.2.3.3 Dearth of skilled radiologists
4.2.3.4 Impact analysis of restraints on market forecast
4.2.4 Opportunities
4.2.4.1 Growing applications of liquid embolic agents
4.2.4.2 Untapped market in developing economies
4.2.4.3 Increasing adoption of image-guided procedures
4.3 Porter’s Five Forces Analysis
Chapter 5. Global Market Size and Forecast
5.1 Global Market Size and Forecast
5.2 By Product
5.2.1 Embolic Agents Market, by Type
5.2.2 Embolotherapy Support Devices Market, by Type
5.3 By Procedure
5.3.1 TAE Market, By Product
5.3.1.1 TAE Embolic Agents Market, by Type
5.3.1.2 TAE Support Devices Market, by Type
5.3.2 TACE Market, By Product
5.3.2.1 TACE Embolic Agents Market, by Type
5.3.2.2 TACE Support Devices Market, by Type
5.3.3 TARE Market, By Product
5.3.3.1 TARE Embolic Agents Market, by Type
5.3.3.2 TARE Support Devices Market, by Type
5.4 By Indication
5.4.1 Embolotherapy Market for Cancer, by Type
5.4.1.1 Liver Cancer Embolotherapy Market, By Product
5.4.1.1.1 Liver Cancer Embolic Agents Market, by Type
5.4.1.2 Kidney Cancer Embolotherapy Market, By Product
5.4.1.2.1 Kidney Cancer Embolic Agents Market, by Type
5.4.1.3 Other Cancer Embolotherapy Market, By Product
5.4.1.3.1 Other Cancer Embolic Agents Market, by Type
5.4.2 Embolotherapy Market for Neurological Diseases, by Type
5.5 By End User
5.6 By Region
Chapter 6. North America Market Size and Forecast
6.1 By Product
6.1.1 Embolic Agents Market, by Type
6.1.2 Embolotherapy Support Devices Market, by Type
6.2 By Procedure
6.2.1 TAE Market, By Product
6.2.1.1 TAE Embolic Agents Market, by Type
6.2.1.2 TAE Support Devices Market, by Type
6.2.2 TACE Market, By Product
6.2.2.1 TACE Embolic Agents Market, by Type
6.2.2.2 TACE Support Devices Market, by Type
6.2.3 TARE Market, By Product
6.2.3.1 TARE Embolic Agents Market, by Type
6.2.3.2 TARE Support Devices Market, by Type
6.3 By Indication
6.3.1 Embolotherapy Market for Cancer, by Type
6.3.1.1 Liver Cancer Embolotherapy Market, By Product
6.3.1.1.1 Liver Cancer Embolic Agents Market, by Type
6.3.1.2 Kidney Cancer Embolotherapy Market, By Product
6.3.1.2.1 Kidney Cancer Embolic Agents Market, by Type
6.3.1.3 Other Cancer Embolotherapy Market, By Product
6.3.1.3.1 Other Cancer Embolic Agents Market, by Type
6.3.2 Embolotherapy Market for Neurological Diseases, by Type
6.4 By End User
6.5 By Country
6.5.1 U.S. Market Size and Forecast
6.5.1.1 By product
6.5.1.1.1 Embolic agents market, by type
6.5.1.1.2 Embolotherapy support devices market, by type
6.5.1.2 By procedure
6.5.1.2.1 TAE Market, By Product
6.5.1.2.1.1 TAE Embolic Agents Market, by Type
6.5.1.2.1.2 TAE Support Devices Market, by Type
6.5.1.2.2 TACE Market, By Product
6.5.1.2.2.1 TACE Embolic Agents Market, by Type
6.5.1.2.2.2 TACE Support Devices Market, by Type
6.5.1.2.3 TARE Market, By Product
6.5.1.2.3.1 TARE Embolic Agents Market, by Type
6.5.1.2.3.2 TARE Support Devices Market, by Type
6.5.1.3 By indication
6.5.1.3.1 Embolotherapy market for cancer, by type
6.5.1.3.2 Liver Cancer Embolotherapy Market, By Product
6.5.1.3.2.1 Liver Cancer Embolic Agents Market, by Type
6.5.1.3.3 Kidney Cancer Embolotherapy Market, By Product
6.5.1.3.3.1 Kidney Cancer Embolic Agents Market, by Type
6.5.1.3.4 Other Cancer Embolotherapy Market, By Product
6.5.1.3.4.1 Other Cancer Embolic Agents Market, by Type
6.5.1.3.5 Embolotherapy market for neurological diseases, by type
6.5.1.4 By end user
6.5.2 Canada Market Size and Forecast
6.5.2.1 By product
6.5.2.1.1 Embolic agents’ market, by type
6.5.2.1.2 Embolotherapy support devices market, by type
6.5.2.2 By procedure
6.5.2.2.1 TAE Market, By Product
6.5.2.2.1.1 TAE Embolic Agents Market, by Type
6.5.2.2.1.2 TAE Support Devices Market, by Type
6.5.2.2.2 TACE Market, By Product
6.5.2.2.2.1 TACE Embolic Agents Market, by Type
6.5.2.2.2.2 TACE Support Devices Market, by Type
6.5.2.2.3 TARE Market, By Product
6.5.2.2.3.1 TARE Embolic Agents Market, by Type
6.5.2.2.3.2 TARE Support Devices Market, by Type
6.5.2.3 By indication
6.5.2.3.1 Embolotherapy market for cancer, by type
6.5.2.3.2 Liver Cancer Embolotherapy Market, By Product
6.5.2.3.2.1 Liver Cancer Embolic Agents Market, by Type
6.5.2.3.3 Kidney Cancer Embolotherapy Market, By Product
6.5.2.3.3.1 Kidney Cancer Embolic Agents Market, by Type
6.5.2.3.4 Other Cancer Embolotherapy Market, By Product
6.5.2.3.4.1 Other Cancer Embolic Agents Market, by Type
6.5.2.3.5 Embolotherapy market for neurological diseases, by type
6.5.2.4 By end user
Chapter 7. Europe Market Size and Forecast
7.1 By Product
7.1.1 Embolic Agents Market, by Type
7.1.2 Embolotherapy Support Devices Market, by Type
7.2 By Procedure
7.2.1 TAE Market, By Product
7.2.1.1 TAE Embolic Agents Market, by Type
7.2.1.2 TAE Support Devices Market, by Type
7.2.2 TACE Market, By Product
7.2.2.1 TACE Embolic Agents Market, by Type
7.2.2.2 TACE Support Devices Market, by Type
7.2.3 TARE Market, By Product
7.2.3.1 TARE Embolic Agents Market, by Type
7.2.3.2 TARE Support Devices Market, by Type
7.3 By Indication
7.3.1 Embolotherapy Market for Cancer, by Type
7.3.1.1 Liver Cancer Embolotherapy Market, By Product
7.3.1.1.1 Liver Cancer Embolic Agents Market, by Type
7.3.1.2 Kidney Cancer Embolotherapy Market, By Product
7.3.1.2.1 Kidney Cancer Embolic Agents Market, by Type
7.3.1.3 Other Cancer Embolotherapy Market, By Product
7.3.1.3.1 Other Cancer Embolic Agents Market, by Type
7.3.2 Embolotherapy Market for Neurological Diseases, by Type
7.4 By End User
7.5 By Country
7.5.1 Germany Market Size and Forecast
7.5.1.1 By product
7.5.1.1.1 Embolic agents market, by type
7.5.1.1.2 Embolotherapy support devices market, by type
7.5.1.2 By procedure
7.5.1.2.1 TAE Market, By Product
7.5.1.2.1.1 TAE Embolic Agents Market, by Type
7.5.1.2.1.2 TAE Support Devices Market, by Type
7.5.1.2.2 TACE Market, By Product
7.5.1.2.2.1 TACE Embolic Agents Market, by Type
7.5.1.2.2.2 TACE Support Devices Market, by Type
7.5.1.2.3 TARE Market, By Product
7.5.1.2.3.1 TARE Embolic Agents Market, by Type
7.5.1.2.3.2 TARE Support Devices Market, by Type
7.5.1.3 By indication
7.5.1.3.1 Embolotherapy market for cancer, by type
7.5.1.3.2 Liver Cancer Embolotherapy Market, By Product
7.5.1.3.2.1 Liver Cancer Embolic Agents Market, by Type
7.5.1.3.3 Kidney Cancer Embolotherapy Market, By Product
7.5.1.3.3.1 Kidney Cancer Embolic Agents Market, by Type
7.5.1.3.4 Other Cancer Embolotherapy Market, By Product
7.5.1.3.4.1 Other Cancer Embolic Agents Market, by Type
7.5.1.3.5 Embolotherapy market for neurological diseases, by type
7.5.1.4 By end user
7.5.2 France Market Size and Forecast
7.5.2.1 By product
7.5.2.1.1 Embolic agents market, by type
7.5.2.1.2 Embolotherapy support devices market, by type
7.5.2.2 By procedure
7.5.2.2.1 TAE Market, By Product
7.5.2.2.1.1 TAE Embolic Agents Market, by Type
7.5.2.2.1.2 TAE Support Devices Market, by Type
7.5.2.2.2 TACE Market, By Product
7.5.2.2.2.1 TACE Embolic Agents Market, by Type
7.5.2.2.2.2 TACE Support Devices Market, by Type
7.5.2.2.3 TARE Market, By Product
7.5.2.2.3.1 TARE Embolic Agents Market, by Type
7.5.2.2.3.2 TARE Support Devices Market, by Type
7.5.2.3 By indication
7.5.2.3.1 Embolotherapy market for cancer, by type
7.5.2.3.2 Liver Cancer Embolotherapy Market, By Product
7.5.2.3.2.1 Liver Cancer Embolic Agents Market, by Type
7.5.2.3.3 Kidney Cancer Embolotherapy Market, By Product
7.5.2.3.3.1 Kidney Cancer Embolic Agents Market, by Type
7.5.2.3.4 Other Cancer Embolotherapy Market, By Product
7.5.2.3.4.1 Other Cancer Embolic Agents Market, by Type
7.5.2.3.5 Embolotherapy market for neurological diseases, by type
7.5.2.4 By end user
7.5.3 U.K. Market Size and Forecast
7.5.3.1 By product
7.5.3.1.1 Embolic agents market, by type
7.5.3.1.2 Embolotherapy support devices market, by type
7.5.3.2 By procedure
7.5.3.2.1 TAE Market, By Product
7.5.3.2.1.1 TAE Embolic Agents Market, by Type
7.5.3.2.1.2 TAE Support Devices Market, by Type
7.5.3.2.2 TACE Market, By Product
7.5.3.2.2.1 TACE Embolic Agents Market, by Type
7.5.3.2.2.2 TACE Support Devices Market, by Type
7.5.3.2.3 TARE Market, By Product
7.5.3.2.3.1 TARE Embolic Agents Market, by Type
7.5.3.2.3.2 TARE Support Devices Market, by Type
7.5.3.3 By indication
7.5.3.3.1 Embolotherapy market for cancer, by type
7.5.3.3.2 Liver Cancer Embolotherapy Market, By Product
7.5.3.3.2.1 Liver Cancer Embolic Agents Market, by Type
7.5.3.3.3 Kidney Cancer Embolotherapy Market, By Product
7.5.3.3.3.1 Kidney Cancer Embolic Agents Market, by Type
7.5.3.3.4 Other Cancer Embolotherapy Market, By Product
7.5.3.3.4.1 Other Cancer Embolic Agents Market, by Type
7.5.3.3.5 Embolotherapy market for neurological diseases, by type
7.5.3.4 By end user
7.5.4 Italy Market Size and Forecast
7.5.4.1 By product
7.5.4.1.1 Embolic agents market, by type
7.5.4.1.2 Embolotherapy support devices market, by type
7.5.4.2 By procedure
7.5.4.2.1 TAE Market, By Product
7.5.4.2.1.1 TAE Embolic Agents Market, by Type
7.5.4.2.1.2 TAE Support Devices Market, by Type
7.5.4.2.2 TACE Market, By Product
7.5.4.2.2.1 TACE Embolic Agents Market, by Type
7.5.4.2.2.2 TACE Support Devices Market, by Type
7.5.4.2.3 TARE Market, By Product
7.5.4.2.3.1 TARE Embolic Agents Market, by Type
7.5.4.2.3.2 TARE Support Devices Market, by Type
7.5.4.3 By indication
7.5.4.3.1 Embolotherapy market for cancer, by type
7.5.4.3.2 Liver Cancer Embolotherapy Market, By Product
7.5.4.3.2.1 Liver Cancer Embolic Agents Market, by Type
7.5.4.3.3 Kidney Cancer Embolotherapy Market, By Product
7.5.4.3.3.1 Kidney Cancer Embolic Agents M
